Tenaya Therapeutics (TNYA) Operating Income (2020 - 2026)
Tenaya Therapeutics' quarterly Operating Income came in at -$20.1 million in Q1 2026, up 27.14% year-on-year from -$15.8 million in Q1 2025, and up 3.42% quarter-over-quarter from -$20.8 million in Q4 2025.
Tenaya Therapeutics has reported Operating Income for 7 years, with the latest figure at -$20.1 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 27.14% year-over-year to -$20.1 million; the trailing twelve-month figure through Mar 2026 stood at -$85.9 million (up 21.75% YoY), and the FY2025 full-year result was -$93.3 million, up 19.51% from the prior year.
- Operating Income for Q1 2026 stood at -$20.1 million, up from -$20.8 million in the prior quarter.
- The five-year high for Operating Income was -$20.1 million in Q1 2026, with the low at -$35.1 million in Q2 2023.
- Average Operating Income over 5 years is -$28.6 million, with a median of -$30.8 million recorded in 2024.
- Year-over-year, Operating Income slumped 137.73% in 2022 and advanced 27.14% in 2026.
- Tracing TNYA's Operating Income over 5 years: stood at -$34.6 million in 2022, then increased by 8.98% to -$31.4 million in 2023, then increased by 21.61% to -$24.7 million in 2024, then gained by 15.73% to -$20.8 million in 2025, then grew by 3.42% to -$20.1 million in 2026.
- The last three Operating Income figures came in at -$20.1 million (Q1 2026), -$20.8 million (Q4 2025), and -$20.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - | -20.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.07 Mn |
| Dec 31, 2025 | -20.78 Mn |
| Sep 30, 2025 | -20.94 Mn |
| Jun 30, 2025 | -24.08 Mn |
| Mar 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | -24.65 Mn |
| Sep 30, 2024 | -26.71 Mn |
| Jun 30, 2024 | -30.82 Mn |
| Mar 31, 2024 | -33.76 Mn |
| Dec 31, 2023 | -31.45 Mn |
| Sep 30, 2023 | -30.92 Mn |
| Jun 30, 2023 | -35.10 Mn |
| Mar 31, 2023 | -33.72 Mn |
| Dec 31, 2022 | -34.55 Mn |
| Sep 30, 2022 | -31.30 Mn |
| Jun 30, 2022 | -28.62 Mn |
| Mar 31, 2022 | -31.15 Mn |
| Dec 31, 2021 | -26.16 Mn |
| Sep 30, 2021 | -18.30 Mn |
| Jun 30, 2021 | -15.24 Mn |
| Mar 31, 2021 | -13.11 Mn |
| Dec 31, 2020 | -10.32 Mn |
| Sep 30, 2020 | -10.45 Mn |
| Jun 30, 2020 | -8.87 Mn |